• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 29, 2024 at 10:52: PM
via Five months ago, Merck & Co. revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar 20. Now, the company is comparing the investigational shot to its old warhorse, Pneumovax 23 (PPSV23).

article source
 

<



Similar threads

cafead
On doorstep of FDA decision, Gilead pays J&amp;J $320M to exit licensing deal for seladelpar
Replies
0
Views
29
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sites on wheels: bringing the clinical trial to the patient’s doorstep
Replies
0
Views
104
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Replies
0
Views
1
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Apple Watch sleep apnea detection gets FDA approval
Replies
0
Views
18
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote